Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iniparib plus Paclitaxel in TNBC
NCT01204125Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2010
- Primary completion
- Oct 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of iniparib in triple-negative breast cancer (TNBC) (3 arms), sponsored by Sanofi. Primary endpoint: Pathological Complete Response rate in the breast. Started Sep 2010; status: completed.
02
Drugs
iniparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01204125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01204125.